Nambour General Hospital, Nambour, QLD
Sunshine Coast University Hospital, Sunshine Coast, QLD.
Med J Aust. 2018 Sep 1;209(7):312-317. doi: 10.5694/mja17.01067.
The gastrointestinal microbiota is emerging as a central factor in the pathogenesis of a range of gastrointestinal and hepatic disorders. Epidemiological studies, and experimental studies in animals and humans, have highlighted a likely causative role of this microbial community in the modern global epidemics of inflammatory bowel disease, non-alcoholic fatty liver disease, non-alcoholic steato-hepatitis, obesity and metabolic syndrome. New techniques for microbial culture and gene sequencing are enabling the identification of specific pathogens and protective organisms in these conditions. Factors that change the microbiota are being defined: dietary pattern, specific foods, food additives in processed food and drinks, such as emulsifiers and non-sugar sweeteners, and antibiotics. Microbiota changes in early life appear critical to the later development of a range of inflammatory disorders. For many of these conditions, the treatment paradigm will change, at least in part, from immune suppression and drug therapy to treatments that reshape the microbiota or restore its integrity. These treatments include dietary changes, specific microbial manipulation and faecal microbiota transplantation. A dialogue is needed regarding population strategies that target disease prevention. This will include how food is produced, what additives it contains, and how it is processed. Widespread use of antibiotics, from agricultural and veterinary to medicinal settings, needs more attention. At the individual level, microbial profiles may be able to predict who is at risk of disease when subjected to particular environmental influences, and what microbial restoration is needed to minimise risk.
肠道微生物群正在成为一系列胃肠道和肝脏疾病发病机制的核心因素。流行病学研究以及动物和人类的实验研究强调了这种微生物群落可能在炎症性肠病、非酒精性脂肪性肝病、非酒精性脂肪性肝炎、肥胖和代谢综合征等现代全球流行病中起致病作用。微生物培养和基因测序的新技术使人们能够在这些疾病中识别出特定的病原体和保护生物。正在定义改变微生物群的因素:饮食模式、特定食物、加工食品和饮料中的食品添加剂,如乳化剂和非糖甜味剂以及抗生素。早期生活中的微生物群变化似乎对一系列炎症性疾病的后期发展至关重要。对于许多这些疾病,治疗模式将发生变化,至少部分将从免疫抑制和药物治疗转变为重塑微生物群或恢复其完整性的治疗方法。这些治疗方法包括饮食变化、特定微生物操作和粪便微生物群移植。需要就针对疾病预防的人群策略进行对话。这将包括食物的生产方式、所含添加剂以及加工方式。从农业、兽医到医疗领域广泛使用的抗生素需要更多关注。在个体层面上,微生物特征可能能够预测在受到特定环境影响时谁有患病风险,以及需要进行哪些微生物恢复以最小化风险。